Resultado de búsqueda
Hace 2 horas · About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.
Hace 8 horas · Together, they founded Faron Pharmaceuticals in 2007, with their children also having roles in the business and development aspect of the company. The Finnish couple behind the innovation has been named one of three finalists in the ‘SMEs’ category for this year’s European Inventor Award.
Hace 8 horas · Proactive Investors - Faron Pharmaceuticals Limited (LON: FARN)’s founders Markku Jalkanen and Sirpa Jalkanen have been selected as finalists for the 2024 European Inventor Award in the SMEs category. Their nomination comes in recognition of their work on bexmarilimab, an investigational immunotherapy aimed at enhancing clinical outcomes in cancer treatment by targeting the Clever-1 receptor ...
Hace 8 horas · Faron Pharmaceuticals Limited (AIM:FARN) ’s founders Markku Jalkanen and Sirpa Jalkanen have been selected as finalists for the 2024 European Inventor Award in the SMEs category. Their ...
Hace 8 horas · Faron founders and bexmarilimab developers selected as finalists for the European Inventor Award 2024 Press Release, May 16, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT) - Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron's co-founders, have been nominated as one of three finalists in the 'SMEs' category of prestigious European Patent Office Awards
Hace 5 días · Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities.
Hace 3 días · REPLACEMENT – BOARD CHANGE-FARON PHARMACEUTICALS OY. Company announcement, April 30, 2024 at 15:00 (EEST) / 1:00 PM (BST) / 8:00 AM (EDT) TURKU, FINLAND / BOSTON, MA Further to the announcement of 8 April 2024, Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to ...
